Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study

CAPTIVATE (NCT02910583), a randomized phase II study, evaluates minimal residual disease (MRD)-guided treatment discontinuation following completion of first-line ibrutinib plus venetoclax treatment in patients with chronic lymphocytic leukemia (CLL). METHODS: Previously untreated CLL patients age &...

Descripción completa

Detalles Bibliográficos
Autores principales: Wierda, William G., Allan, John N., Siddiqi, Tanya, Kipps, Thomas J., Opat, Stephen, Tedeschi, Alessandra, Badoux, Xavier C., Kuss, Bryone J., Jackson, Sharon, Moreno, Carol, Jacobs, Ryan, Pagel, John M., Flinn, Ian, Pak, Yvonne, Zhou, Cathy, Szafer-Glusman, Edith, Ninomoto, Joi, Dean, James P., James, Danelle F., Ghia, Paolo, Tam, Constantine S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713593/
https://www.ncbi.nlm.nih.gov/pubmed/34618601
http://dx.doi.org/10.1200/JCO.21.00807

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8713593/
https://www.ncbi.nlm.nih.gov/pubmed/34618601
http://dx.doi.org/10.1200/JCO.21.00807

Ejemplares similares